Spinogenix's Tazbentetol Shows Rapid Cognitive Improvement in Alzheimer's Disease Phase 2 Trial
核心洞察
Tazbentetol (搜索) demonstrated a >2.5-point improvement in Mini-Mental State Exam scores within four weeks of treatment in patients with mild-to-moderate Alzheimer's disease.
The synaptogenic small molecule showed sustained cognitive benefits across multiple endpoints including CDR-SB and ADL scores over 24 weeks with continued improvement at 40 weeks.
The FDA has accepted an investigational new drug application for tazbentetol (搜索), positioning it as a potential first-in-class regenerative therapy for Alzheimer's disease.
Spinogenix (搜索)'s investigational drug tazbentetol (搜索) has demonstrated rapid cognitive improvements in patients with mild-to-moderate Alzheimer's disease, showing a >2.5-point average increase in standardized Mini-Mental State Examination (SMMSE) scores versus placebo within just four weeks of treatment in a Phase 2 trial.
The randomized, double-blind, placebo-controlled study (NCT06427668) enrolled 24 participants across two cohorts in Australia, with patients randomized 2:1 to receive either placebo or active treatment at 300-mg or 150-mg doses. According to Bruce Brew, MD, DSc, FRACP, FAAN, who led the trial and serves as director of the Peter Duncan Neurosciences Unit at St Vincent's Hospital in Sydney, "At week 4, we found that the Mini-Mental State Exam score improved by around 2.5-plus points. So that's quite dramatic. I can't think of really any other intervention that's comparable at such a rapid, early time point."
Sustained Cognitive Benefits Across Multiple Measures
The cognitive improvements observed with tazbentetol (搜索), formerly known as SPG302, were sustained throughout the 24-week open-label extension period. Similar positive effects were documented across other primary endpoints, including Clinical Dementia Rating Sum of Boxes (CDR-SB) and Activities of Daily Living (ADL) values.
Patients who continued treatment for an additional 52 weeks experienced increasing benefits, with both ADL and CDR-SB scores showing improvements over baseline measures after 40 weeks of total treatment. The drug also demonstrated effects on neurophysiological biomarkers, with patients experiencing a reversal of cortical "slowing" as measured through electroencephalogram (EEG) scans, indicating impacts on synaptic regeneration.
Novel Mechanism Targets Synaptic Loss
Tazbentetol (搜索) represents a novel approach to Alzheimer's treatment as a synaptogenic small molecule that specifically targets synaptic degradation. According to Spinogenix (搜索) CEO Stella Sarraf, preventing synaptic loss could be a promising strategy in Alzheimer's disease, as it addresses what the company believes is "a major driver of cognitive decline and memory loss in the early stages of Alzheimer's disease progression."
This mechanism of action differentiates tazbentetol (搜索) from currently approved disease-modifying therapies such as Eli Lilly's Kisunla (donanemab) and Biogen & Eisai's Leqembi (lecanemab). Sarraf noted that drugs like tazbentetol could be employed alongside both symptom-managing cholinesterase inhibitors and existing DMTs.
Safety Profile and Regulatory Progress
The once-daily oral treatment demonstrated an acceptable safety profile throughout the study period. No severe treatment-emergent adverse events were observed when tazbentetol (搜索) was used either as monotherapy or in combination with standard-of-care cholinesterase inhibitors.
The FDA has accepted an investigational new drug (IND) application for tazbentetol (搜索) in Alzheimer's disease, which will facilitate initiation of what Spinogenix (搜索) describes as a "registrational or registrational-directed study." According to Chief Commercial Officer Sharron Gargosky, the company will continue communications with the FDA to guide next steps for the drug's development.
Market Potential and Broader Applications
If approved, tazbentetol (搜索) could become the first regenerative drug to obtain FDA approval for Alzheimer's disease, entering a market that GlobalData estimates will be worth $19.3 billion by 2033. The drug offers potential advantages in clinical practice, as Sarraf noted that it does not require PET scans to determine patient suitability—only a general diagnosis is needed.
Beyond mild-to-moderate Alzheimer's disease, Spinogenix (搜索) is exploring tazbentetol (搜索)'s potential in both preventive and late-stage settings. The company has also reported positive results for the drug in amyotrophic lateral sclerosis (ALS), where it triggered stable or improved rates of ALS-associated decline in 82% of patients during a mid-stage study, leading to advancement to a registrational trial. Additionally, a Phase 2 trial in schizophrenia is currently underway.
According to Philippa Salter, managing neurology analyst at GlobalData, key opinion leaders have highlighted the important unmet need in the Alzheimer's market for effective drugs targeting cognition. "If the positive results can be replicated in a large, pivotal, placebo-controlled trial, then tazbentetol (搜索) has the potential to meet this unmet need," Salter said. "As an oral drug with a favourable safety profile, it would be easy to incorporate into the treatment algorithm."